Versiti - Lisa Baumann Kreuziger, MD, MS | Versiti Blood Research Institute

Lisa Baumann Kreuziger, MD, MS

Lisa Baumann Lisa Baumann profile

Lisa Baumann Kreuziger, MD, MS

Senior Medical Director, Hematology, Investigator

Senior Medical Director, Hematology
Versiti Medical Science Institute
Investigator
Versiti Blood Research Institute

Associate Professor
Department of Medicine
Medical College of Wisconsin

Contact Information

Dr. Baumann Kreuziger specializes in non-malignant hematology with an emphasis on patients with clotting and bleeding disorders.  Dr. Baumann Kreuziger is interested in the underlying mechanisms of thrombosis and optimal treatment strategies for patients with thrombosis.

She leads the Venous thromboEmbolism Network United States (VENUS). More information can be found here: https://www.venusresearch.org.

  • ACTIV-4 Clinical Trial Platforms
  • American Society of Hematology
  • Recipient Epidemiology and Donor Evaluation Study IV (REDS IV-P) (co PI-Mast)
  • INVENT Kickstarter Award

Stephanie Jones, MS, CCRC
Quality and Research Supervisor

Rae Janecke, CCRC
Senior Clinical Research Coordinator


Courtney Conway
CTRO Supervisor

Joseph Sibley
Associate Clinical Research Coordinator

Shane Howe
Associate Clinical Research Coordinator

For a full list of Dr. Baumann Kreuziger's publications Click Here (Redirects to NCBI).

Selected Publications
  • Wu JF, Malec LM, Pandit S, Abid H, Jha P, Baumann Kreuziger LM. A 10-year single-institution retrospective review of treatment for acquired hemophilia A. Haemophilia. 2023 Sep 11. doi: 10.1111/hae.14856. Epub ahead of print. PMID: 37694801.
  • Wang TY, Wahed AS, Morris A, Kreuziger LB, Quigley JG, Lamas GA, Weissman AJ, Lopez-Sendon J, Knudson MM, Siegal DM, Kasthuri RS, Alexander AJ, Wahid L, Atassi B, Miller PJ, Lawson JW, Patel B, Krishnan JA, Shapiro NL, Martin DE, Kindzelski AL, Leifer ES, Joo J, Lyu L, Pennella A, Everett BM, Geraci MW, Anstrom KJ, Ortel TL; ACTIV-4C Study Group. Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization. Ann Intern Med. 2023 Apr;176(4):515-523. doi: 10.7326/M22-3350. Epub 2023 Mar 21. PMID: 36940444; PMCID: PMC10064277.
  • Held N, Jung B, Baumann Kreuziger L. Management of cancer-associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement. Res Pract Thromb Haemost. 2022 May 25;6(4):e12726. doi: 10.1002/rth2.12726. PMID: 35664532; PMCID: PMC9133434.
  • Baumann Kreuziger L, Feng M, Bartosic A, Simpson P, Wang TF. A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal. Blood Coagul Fibrinolysis. 2022 Jan 3. doi: 10.1097/MBC.0000000000001122. Epub ahead of print. PMID: 34980834.
  • Sholzberg M, da Costa BR, Tang G….Baumann Kreuziger LM,Peter Jüni MD, the RAPID Trial Investigators. Randomized trials of therapeutic heparin for COVID-19: A meta- analysis. Res Pract Thromb Haemost. 2021;5:e12638.https://doi.org/10.1002/rth2.12638.
  • COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/
  • Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, ……Cushman M, Jüni P; RAPID trial investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400. PMID: 34649864; PMCID: PMC8515466
  • ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, ….Baumann Kreuziger L…., Farkouh ME, Hochman JS, Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. NEJM/New England Journal of Medicine. 2021 Aug 4. doi: 10.1056/NEJMoa2105911.
  • Baumann Kreuziger L, Feng M, Bartosic A, Simpson P, Wang TF. A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal. Blood Coagul Fibrinolysis. 2022 Jan 3. doi: 10.1097/MBC.0000000000001122. Epub ahead of print. PMID: 34980834.
  • Held N, Jung B, Baumann Kreuziger L. Management of cancer-associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement. Res Pract Thromb Haemost. 2022 May 25;6(4):e12726. doi: 10.1002/rth2.12726. PMID: 35664532; PMCID: PMC9133434.
  • Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Antithrombotic Therapy for VTE Disease: Second Update of the CHESTGuideline and Expert Panel Report – Executive Summary, CHEST (2021), doi: https://doi.org/10.1016/j.chest.2021.07.056.
  • Kreuziger LB, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Jaglal M, Houghton DE, Streiff MB, Gali R, Feng M, Simpson P, Billett HH. Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. Thromb Res. 2021 Jun;2020:155-161. doi: 10.1016/j.thromres.2021.03.021. Epub 2021 Apr 6. PMID: 33862470.
  • Houghton DE, Billett HH, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Feng M, Dasgupta M, Jaglal M, Streiff MB, Simpson P, Gali R, Baumann Kreuziger L. Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. Blood Adv. 2021 Jul 27;5(14):2807-2812. doi: 10.1182/bloodadvances.2021004698. PMID: 34264267. 
  • Kreuziger LB, Edgren G, Hauser RG, Zaccaro D, Kiss J, Westlake M, Brambilla D, Mast AE. Red Blood Transfusion Does Not Increase Risk of Venous or Arterial Thrombosis. Am J Hematol. 2021 Feb 1;96(2):218-225. doi: 10.1002/ajh.26038. Epub 2020 Nov 16.
  • Rosovsky RP, Sanfilippo KM, Wang TF, Rajan SK, Shah S, Martin KA, Ni Ainle F, Huisman M, Hunt BJ, Khan SR, Kevane B, Lee AYY, McLintok C, Kreuziger LB. Anticoagulation Practice Patterns in COVID‐19: A Global Survey. Res Prac Thromb Haemost. 2020 Jul 9;4(6):969-83. doi:10.1002/rth2.12414
  • Held N, Jung B, Sommervold L, Sing S, Kreuziger LB.  Patient safety indicator-12 rarely identifies problems with quality of care in perioperative venous thromboembolism. J Hosp Med. 2019 Nov 20;14:E1-E6. PMID: 31995470
 
Thrombosis & Hemostasis
We study the properties of blood that cause it to clot. Our findings help to treat diseases that cause blood clots or excessive bleeding.
 
VENUS thromboEmbolism Network U.S. (VENUS)
Versiti supports the clinical coordinating center for VENUS, which initiates and implements clinical trials and research projects for thrombotic disorders.
 
Our Experts
Research investigators, postdoctoral fellows and laboratory staff at Versiti Blood Research Institute and Diagnostic Laboratories.
 
Versiti Blood Research Institute
Versiti Blood Research Institute investigators study blood disorders like hemophilia, blood cancers like leukemia, and other blood diseases.